Stayble Therapeutics Investor Relations Material
Latest events
CEO Sitdown with Kalqyl Q4 2023
Stayble Therapeutics
Q1 2025
21 May, 2025
Q4 2024
25 Feb, 2025
Access the full event backlog
Slides, Transcripts, and Reports from 13,000 public companies
Latest reports from Stayble Therapeutics
Access all reports
Stayble Therapeutics is a clinical-stage biotechnology company developing non-surgical treatments for chronic disc-related back pain. Its lead candidate targets degenerative disc disease using injectable therapeutics. The company is headquartered in Gothenburg, Sweden, and its shares are listed on the Nasdaq First North Growth Market.
Latest articles
)
Citadel: Relentless Optimization at Global Scale
From a Harvard dorm to global dominance, this is the story of how Ken Griffin created one of the best-performing hedge funds of all time.
4 Jul 2025
)
David A. Ricks: Eli Lilly's Chairman and CEO
David Ricks built a decades-long career at Eli Lilly, now leading the giant company through a defining moment in its long pharmaceutical history.
3 Jul 2025
)
D. E. Shaw & Co: Inside the Quiet Giant of Quant Finance
A deep dive into D. E. Shaw's evolution from a $28M quant startup to a $65B hedge fund giant, built on research, computing, and quiet consistency.
2 Jul 2025
Ticker symbol
STABL
Country
🇸🇪 Sweden